Related Experiment Videos
Fluconazole improves survival in septic shock: a randomized double-blind prospective study
Sydney Jacobs1, David A Price Evans, Mohammed Tariq
1Department of Anesthesia and Intensive Care, Riyadh Armed Forces Hospital, Saudi Arabia. sydney@nesma.net.sa
Critical Care Medicine
|July 9, 2003
Summary
Fluconazole significantly reduced mortality and organ failure in patients with early septic shock. This antifungal agent demonstrated greater efficacy in intra-abdominal sepsis cases, improving survival rates.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pharmacology
Background:
- Sepsis is a life-threatening condition characterized by organ dysfunction.
- Early intervention is crucial for improving outcomes in septic shock.
- The role of antifungal agents in non-fungal sepsis requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of fluconazole in reducing multiple organ failure and mortality in patients with early septic shock.
- To compare the effects of fluconazole versus placebo in a critically ill patient population.
Main Methods:
- Prospective, randomized, double-blind study conducted in a tertiary referral center's ICU.
- 71 adult patients with early septic shock (onset <24 hours) were enrolled.
- Patients received either intravenous fluconazole (200 mg daily) or isotonic saline placebo.
Main Results:
- Fluconazole treatment significantly increased 30-day survival rates (78% vs. 46% in placebo).
- The drug was more effective in septic shock attributed to intra-abdominal sepsis than nosocomial pneumonia.
- Fluconazole led to a lower incidence of organ failure in the intra-abdominal sepsis subgroup.
Conclusions:
- Intravenous fluconazole significantly reduced organ failure and mortality in early septic shock.
- Fluconazole's protective effect may involve enhanced neutrophil function and localized microbial containment.
- Further research is needed to elucidate the precise mechanisms of fluconazole's benefit in septic shock.